Table 1.
Author | Year | Characteristic of hydrogen peroxide | Concentration of hydrogen peroxide | Action time | Ventilation time | Virus inactivated |
---|---|---|---|---|---|---|
Kindermann et al. (Kindermann et al., 2020) | 2020 | Vapour | 33.8% | 11–55 min | — | BVDV, HAV, MVM, Reo III |
Holmdahl et al. (Holmdahl, Odenholt, Riesbeck, Medstrand, & Widell, 2019) | 2019 | Vapour | 860 ppm | 33 min | 50 min | HuNoV |
Montazeri et al. (Montazeri et al., 2017) | 2017 | Vapour | 7.5% | 5 min | 20 min | FCV, HuNoV |
Becker et al. (Becker, Bischoff, Brill, Steinmann, & Steinmann, 2017) | 2017 | Solution | 40%–60% | 30 s–3 min | — | ADV, MNV, MVM, poliovirus, Vaccinia virus, |
Baker et al. (Baker et al., 2017) | 2017 | Foam | 4.25% | 40 and 50 min | — | PEDV, PRCV |
Holtkamp et al. (Holtkamp et al., 2017) | 2017 | Foam | 4.25% | 30 min | — | PEDV |
Zonta et al. (Zonta, Mauroy, Farnir, & Thiry, 2016) | 2016 | Aerosol | 7% | 1 min and 30 s | 60 min | FCV, MNV |
Holmdahl et al. (Holmdahl et al., 2016) | 2016 | Vapour | 30%–35% | 40–50 min | 15 min | FCV, MNV |
Ryndock et al. (Ryndock, Robison, & Meyers, 2016) | 2016 | Sonicated | 31.5% and 35% | 2 min | — | HPV16, HPV18 |
Goyal et al. (Goyal et al., 2014) | 2014 | Vapour | 35% | 20 min | Approximately 2 hr | AIV, hADV−1, FCV, SARS virus, TGEV |
Tuladhar et al. (Tuladhar, Terpstra, Koopmans, & Duizer, 2012) | 2012 | Vapour | 12% | 45 min | 70 min | hADV−1, HuNoV, H1N1, MNV, Poliovirus, rotavirus |
Abbreviations: ADV, adenovirus; BVDV, bovine viral diarrhea virus; FCV, feline calicivirus; H1N1‐influenza; hADV‐1, human adenovirus type1; HAV, hepatitis A virus; HPV, human papillomavirus; HuNoV, human noroviruses; MNV, Murine norovirus; MVM, Minute virus of mice; PEDV, porcine epidemic diarrhea virus; PRCV, Porcine respiratory corona virus; Reo III, respiratory enteric orphan virus type III; SARS, severe acute respiratory syndrome virus; TGEV, transmissible gastroenteritis virus.